undamentalytics Newsletter
Sign in

ANI Pharmaceuticals Inc cash flow statement

In fiscal 2025, ANI Pharmaceuticals Inc's operations generated $185m of cash; it spent $13.8m on capital projects, leaving free cash flow of $171m. It returned $1.2m in dividends and $12.2m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−18−40−48−0−5221727396746153−3111964185189
Depreciation and amortisation00011472228344545475760689186
Stock-based pay1110034667913101521293841
Capital spending0010012510676399161416
Free cash flow−19−40−49−0−621152329613991−4011048171173
Free cash flow after stock pay−20−41−50−0−6171117235530−4−10−558918133132
Dividends paid——————————00022210
Share buybacks———000030012125111222
Shares issued1148243——————007008100—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ANIP vs HRMYANIP vs PBHANIP vs AXSMANIP vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from ANI Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ANI Pharmaceuticals Inc.